EUCTR2020-002686-33-DK进行中（未招募）1 期
A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - ECHELON-3
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Seagen Inc.
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Participants with relapsed or refractory diffuse and transformed large
- •B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-
- •GCB) will be histologically determined by the most recent local pathology
- •assessment for the purposes of study eligibility and stratification.
- •- Participants must have R/R disease following 2 or more lines of prior
- •systemic therapy. For subjects with transformed DLBCL (subtype k), at
- •least the last systemic therapy used must have been for DLBCL.
- •- Participants must be HSCT or CAR-T ineligible according to the
- •investigator and must meet at least one of the following criteria:
- •1. One or more co-morbidities, including cardiac, pulmonary, renal or
- •hepatic dysfunction that in the opinion of the Investigator make the
- •subject medically unfit to received HSCT or CAR-T therapy
- •2. Active disease following induction and salvage chemotherapy
- •3.Inadequate stem cell mobilization (for HSCT)
- •4. Relapse following prior HSCT or CAR-T
- •5. Unable to receive CAR-T therapy due to financial, geographic,
- •insurance or manufacturing issues
- •- Participants must have tumor tissue submitted to the central pathology
- •lab for the determination of CD30 expression.
- •- An Eastern Cooperative Oncology Group (ECOG) performance status
- •score of 0 to 2
- •- Participants must have fluorodeoxyglucose (FDG)-avid disease by
- •positron emission tomography (PET) and bidimensional measurable
- •disease of >1.5 cm by computed tomography (CT), as assessed by the
- •site radiologist within 28 days of Day 1.
- •Other protocol defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 320
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •- History of another malignancy within 2 years before the first dose of
- •study drug or any evidence of residual disease from a previously
- •diagnosed malignancy
- •- History of progressive multifocal leukoencephalopathy (PML)
- •- Active cerebral/meningeal disease related to the underlying
- •malignancy. Subjects with a history of cerebral/meningeal disease
- •related to the underlying malignancy are allowed if prior CNS disease
- •has been effectively treated and without progression for at least 3
- •- Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral,
- •bacterial, or fungal infection within 2 weeks prior to the first dose of
- •study drug. Routine antimicrobial prophylaxis is permitted
- •- Chemotherapy, radiotherapy, biologics, and/or other antitumor
- •treatment with immunotherapy that is not completed 3 weeks prior to
- •first dose of study drug, unless underlying disease has progressed on
- •- Participants who are breastfeeding
- •- Known hypersensitivity to any study drug or excipient contained in the
- •drug formulation of the study drugs
- •- Any contraindication to associated study treatments.
- •- Known to be positive for hepatitis B by surface antigen expression.
- •Subjects who are hepatitis B core antigen (HBsAg) negative but hepatitis
- •B surface antibody (HBcAb) positive are eligible, but should start
- •hepatitis B prophylaxis therapy prior to receiving the first dose of
- •rituximab. Known to be positive for hepatitis C (HCV) infection (either
- •confirmed positive by polymerase chain reaction [PCR] or on antiviral
- •therapy for hepatitis C within the last 6 months). Participants who have
- •been treated for hepatitis C infection are permitted if they have
- •documented sustained virologic response of 12 weeks.
- •- Participants with previous allogeneic HSCT if they meet either of the
- •following criteria:
- •1.<100 days from HSCT
- •2.Active acute or chronic graft-versus-host disease (GVHD) or receiving
- •immunosuppressive therapy as treatment for or prophylaxis against
- •- Previous treatment with brentuximab vedotin or lenalidomide. Previous
- •treatment with other vedotin-based ADCs is permitted if the last dose is
- •at least 6 months prior to Day 1.
- •- Current therapy with immunosuppressive medications (including
- •steroids), other systemic anti-neoplastic, or investigational agents
- •a) Prednisone (or equivalent) =10 mg/day may be used for non-
- •lymphomatous purposes
- •- Documented history of a cerebral vascular event (stroke or transient
- •ischemic attack), unstable angina, myocardial infarction, pulmonary
- •embolism, or cardiac symptoms consistent with New York Heart
- •Association (NYHA) Class III-IV within 6 months prior to the first dose
- •of study drugs
- •- Congestive heart failure, Class III or IV, by the NYHA criteria
- •- Grade 2 or higher peripheral sensory or motor neuropathy at baseline
- •Other protocol defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCEUCTR2020-002686-33-FRSeattle Genetics, Inc.400
进行中（未招募）
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCdiffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2020-002686-33-PLSeagen Inc.400
撤回
3 期
A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)DLBCLNL-OMON52039Seagen Inc.4
进行中（未招募）
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCdiffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2020-002686-33-CZSeagen, Inc.400
进行中（未招募）
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCEUCTR2020-002686-33-DESeagen Inc.400